Eleanor Burnett1, Jacqueline E Tate2, Carl D Kirkwood3, E Anthony S Nelson4, Mathuram Santosham5, A Duncan Steele3, Umesh D Parashar2. 1. a CDC Foundation for Division of Viral Diseases, Centers for Disease Control and Prevention , Atlanta , GA , USA. 2. b Division of Viral Diseases , Centers for Disease Control and Prevention , Atlanta , GA , USA. 3. c Enteric & Diarrheal Diseases, Global Health , Bill and Melinda Gates Foundation , Seattle , WA , USA. 4. d Department of Paediatrics , Prince of Wales Hospital , Hong Kong Special Administrative Region , PR China. 5. e International Health , Johns Hopkins University , Baltimore , MD , USA.
Abstract
BACKGROUND: Of the 215,000 global deaths from rotavirus estimated in 2013, 41% occur in Asian countries. However, despite a recommendation for global rotavirus vaccination since 2009, only eight countries in Asia have introduced the rotavirus vaccine into their national immunization program as of September 2017. To help policy makers assess the potential value of vaccination, we projected the reduction in rotavirus hospitalizations and deaths following a hypothetical national introduction of rotavirus vaccines in all countries in Asia using data on national-level rotavirus mortality, <5 population, rotavirus hospitalizations rates, routine vaccination coverage, and vaccine effectiveness. METHODS: To quantify uncertainty, we generated 1,000 simulations of these inputs. RESULTS: Our model predicted 710,000 fewer rotavirus hospitalizations, a 49% decrease from the 1,452,000 baseline hospitalizations and 35,000 fewer rotavirus deaths, a 40% decrease from the 88,000 baseline deaths if all 43 Asian countries had introduced rotavirus vaccine. Similar reductions were projected in subanalyses by vaccine introduction status, subregion, and birth cohort size. CONCLUSION: Rotavirus vaccines will substantially reduce morbidity and mortality due to rotavirus infections in Asia.
BACKGROUND: Of the 215,000 global deaths from rotavirus estimated in 2013, 41% occur in Asian countries. However, despite a recommendation for global rotavirus vaccination since 2009, only eight countries in Asia have introduced the rotavirus vaccine into their national immunization program as of September 2017. To help policy makers assess the potential value of vaccination, we projected the reduction in rotavirus hospitalizations and deaths following a hypothetical national introduction of rotavirus vaccines in all countries in Asia using data on national-level rotavirus mortality, <5 population, rotavirus hospitalizations rates, routine vaccination coverage, and vaccine effectiveness. METHODS: To quantify uncertainty, we generated 1,000 simulations of these inputs. RESULTS: Our model predicted 710,000 fewer rotavirus hospitalizations, a 49% decrease from the 1,452,000 baseline hospitalizations and 35,000 fewer rotavirus deaths, a 40% decrease from the 88,000 baseline deaths if all 43 Asian countries had introduced rotavirus vaccine. Similar reductions were projected in subanalyses by vaccine introduction status, subregion, and birth cohort size. CONCLUSION: Rotavirus vaccines will substantially reduce morbidity and mortality due to rotavirus infections in Asia.
Authors: Lucia Helena de Oliveira; M Carolina Danovaro-Holliday; N Jennifer Sanwogou; Cuauhtemoc Ruiz-Matus; Gina Tambini; Jon Kim Andrus Journal: Pediatr Infect Dis J Date: 2011-01 Impact factor: 2.129
Authors: Guillermo M Ruiz-Palacios; Irene Pérez-Schael; F Raúl Velázquez; Hector Abate; Thomas Breuer; SueAnn Costa Clemens; Brigitte Cheuvart; Felix Espinoza; Paul Gillard; Bruce L Innis; Yolanda Cervantes; Alexandre C Linhares; Pío López; Mercedes Macías-Parra; Eduardo Ortega-Barría; Vesta Richardson; Doris Maribel Rivera-Medina; Luis Rivera; Belén Salinas; Noris Pavía-Ruz; Jorge Salmerón; Ricardo Rüttimann; Juan Carlos Tinoco; Pilar Rubio; Ernesto Nuñez; M Lourdes Guerrero; Juan Pablo Yarzábal; Silvia Damaso; Nadia Tornieporth; Xavier Sáez-Llorens; Rodrigo F Vergara; Timo Vesikari; Alain Bouckenooghe; Ralf Clemens; Béatrice De Vos; Miguel O'Ryan Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: Lucia Helena de Oliveira; M Carolina Danovaro-Holliday; Cuauhtemoc Ruiz Matus; Jon Kim Andrus Journal: Expert Rev Vaccines Date: 2008-04 Impact factor: 5.217
Authors: K B Phua; F S Lim; Y L Lau; E A S Nelson; L M Huang; S H Quak; B W Lee; Y L Teoh; H Tang; I Boudville; L C Oostvogels; P V Suryakiran; I V Smolenov; H H Han; H L Bock Journal: Vaccine Date: 2009-08-11 Impact factor: 3.641
Authors: K Zaman; Duc Anh Dang; John C Victor; Sunheang Shin; Md Yunus; Michael J Dallas; Goutam Podder; Dinh Thiem Vu; Thi Phuong Mai Le; Stephen P Luby; Huu Tho Le; Michele L Coia; Kristen Lewis; Stephen B Rivers; David A Sack; Florian Schödel; A Duncan Steele; Kathleen M Neuzil; Max Ciarlet Journal: Lancet Date: 2010-08-06 Impact factor: 79.321
Authors: Le T Luan; Nguyen V Trang; Nguyen M Phuong; Huong T Nguyen; Huong T Ngo; Huong T M Nguyen; Hanh B Tran; Ha N Dang; Anh D Dang; Jon R Gentsch; Yuhuan Wang; Mathew D Esona; Roger I Glass; A Duncan Steele; Paul E Kilgore; Man V Nguyen; Baoming Jiang; Hien D Nguyen Journal: Vaccine Date: 2009-11-20 Impact factor: 3.641
Authors: A D Steele; J C Victor; M E Carey; J E Tate; D E Atherly; C Pecenka; Z Diaz; U D Parashar; C D Kirkwood Journal: Hum Vaccin Immunother Date: 2019-02-08 Impact factor: 3.452
Authors: Rachel M Burke; Jacqueline E Tate; Carl D Kirkwood; A Duncan Steele; Umesh D Parashar Journal: Curr Opin Infect Dis Date: 2019-10 Impact factor: 4.915